Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2020 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche partners with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials

Moderna’s vaccine triggers an antibody response to the SARS-CoV-2 spike proteinThe Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in vaccine trial...
December 08, 2020 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche presents new data from its bispecific antibody portfolio across a range of blood cancers

Latest data to be presented at ASH 2020 includes results in non-Hodgkin lymphoma and heavily pre-treated multiple myeloma Portfolio includes two CD20xCD3 bispecifics, mosunetuzumab and glofitamab, and...
December 07, 2020 01:04 ET | Source: F. Hoffmann-La Roche Ltd

New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma

Longer-term data from the GO29365 study and results from 106 additional patients show continued survival benefit of this fixed-duration, off-the-shelf, Polivy combination Polivy is already approved in...
December 07, 2020 01:00 ET | Source: F. Hoffmann-La Roche Ltd

New follow-up phase III data reinforce the long-term benefit of Roche’s Hemlibra for people with haemophilia A

With nearly three years of follow-up, Hemlibra maintained low treated bleed rates and was well tolerated in people with haemophilia A of all ages, with and without factor VIII inhibitorsThe proportion...
December 05, 2020 12:45 ET | Source: F. Hoffmann-La Roche Ltd

Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia

Long-term follow-up data from the phase III MURANO trial showed sustained progression-free survival with fixed-duration Venclexta/Venclyxto plus MabThera/Rituxan MURANO and phase III CLL14 trials...
December 02, 2020 01:03 ET | Source: F. Hoffmann-La Roche Ltd

Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers

Basel, 2 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adult and...
December 02, 2020 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies

Elecsys® Anti-SARS-CoV-2 S test specifically detects antibodies against the SARS-CoV-2 spike proteinThe spike protein is the target of many COVID-19 vaccines in developmentThis test may help identify...
December 01, 2020 12:07 ET | Source: F. Hoffmann-La Roche Ltd

FDA approves Xolair® (omalizumab) for adults with nasal polyps

Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammationXolair is now FDA-approved across three diseases and in two...
November 24, 2020 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person

Xofluza is the first single-dose influenza medicine approved to prevent influenza for those who have had contact with an infected person (post-exposure prophylaxis) Roche also provides an update on...
November 16, 2020 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche zum elften Mal als nachhaltigstes Gesundheitsunternehmen im Dow Jones Sustainability Index ausgezeichnet

Diese Auszeichnung würdigt das Engagement von Roche für Nachhaltigkeit als integraler Bestandteil der GeschäftsstrategieRoche überzeugte insbesondere in den Bereichen Marketingpraktiken, Umwelt- und...